12 September 2018
A new report by visiongain forecasts the world market for inflammatory bowel disease medicines will reach $9.3 billion in 2019. That revenue prediction and others appear in Inflammatory Bowel Diseases (IBD) 2016-2026: Revenue Forecasts and R&D for Aminosalicylates, Antibiotics, Corticosteroids, Biologics and Immunomodulators Treating Disorders Including Crohn’s Disease and Ulcerative Colitis. Visiongain, a business information publisher and consultancy in London, UK, published that study in January 2016.
Visiongain predicts that the IBD pharmaceuticals market will grow in revenues owing to the increasing use of biological therapies (biologics), such as monoclonal antibodies (mAbs). Although biologics account for a small part of prescriptions at present, they dominate the market for revenue generation and held 68% of the global IBD market in 2014. From 2016 that worldwide market will be stimulated by rising disease incidence and non-invasive diagnosis, as well as technological advances in medicines. That industry’s R&D holds promise.
Sandra Wenas, a senior pharmaceutical industry analyst in visiongain, said: “The worldwide inflammatory bowel drug market will show moderate sales growth over the next four years from 2016. Patent expiries for Humira and Remicade during our forecast period will bring the market value significantly lower. New drugs entering the market are not expected to offset this loss.
“An increased use of biologics will be the main sales driver to 2026. As more doctors advocate the top-down therapy approach, and more studies justify the cost effectiveness of monoclonal antibodies for IBD, biological drugs’ revenues will expand and claim 57% of the IBD treatment market’s revenues by 2026. Aminosalicylates, however, will remain an important option for patients, especially those in poor countries, as the cost advantage of aminosalicylates will be more pronounced in those regions.”
Visiongain’s new analysis shows revenue forecasts to 2026 at overall world market, submarket, product and national level. First it forecasts five world-level submarkets:
• Biologics, including monoclonal antibodies (mAbs)
That investigation next predicts the revenues of 17 leading IBD drugs to 2026, including Humira, Remicade, Asacol, Pentasa, Lialda, Tysabri, Cimzia, Entocort and recently approved treatments Uceris, Simponi and Entyvio.
Visiongain’s analysis includes trends and revenue predictions of 11 leading national markets to 2026:
• EU5:Germany, France, UK, Spain and Italy
• BRIC: Brazil, Russia, India and China.
The study also discusses research and development, including agents in these classes:
• Interleukin (IL) inhibitors
• Cell-adhesion molecule (CAM) inhibitors
• TNF-alpha inhibitors
• Stem cell therapies
• JAK inhibitors
• Toll-like receptor agonists.
That new report includes qualitative analyses and interviews with two authorities in that field. It also discusses leading companies: AbbVie, Janssen Biotech, Allergan and Shire Pharmaceuticals.
Inflammatory Bowel Diseases (IBD) 2016-2026 adds to visiongain’s range of analytical reports on industries and markets in healthcare. Those studies cover pharmaceuticals, biotechnologies, medical devices, diagnostics and contract services.
Penicillin segment holds majority of the market share owing to maximum prescription as well as the most generic manufacturers throughout the industry.
22 June 2021
Over the last few years, companion diagnostics has gained widespread attention due to the technological advancements, growing demand for precision medicine, and accelerating demand for targeted therapy.
17 June 2021
Increasing prevalence of cancers and rising demand for advanced therapies for cancer treatment are the major factors driving the demand for cellular immunotherapies.
15 June 2021
Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions.